Minimal residual disease detection in lymphoma: methods, procedures and clinical significance
Open Access
- 12 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1430070
Abstract
Lymphoma is a highly heterogeneous lymphohematopoietic tumor. As our understanding of the biological and pathological characteristics of lymphoma improves, we are identifying an increasing number of lymphoma subtypes. Genotyping has enhanced our ability to diagnose, treat, and monitor the prognosis of lymphoma. Despite significant improvements in treatment effectiveness, traditional methods for assessing disease response and monitoring prognosis are imperfect, and there is no significant improvement in overall remission rates for lymphoma patients. Minimal Residual Disease (MRD) is often indicative of refractory disease or early relapse. For lymphoma patients, personalized MRD monitoring techniques offer an efficient means to estimate disease remission levels, predict early relapse risk, and assess the effectiveness of new drug regimens. In this review, we delve into the MRD procedures in lymphoma, including sample selection and requirements, detection methods and their limitations and advantages, result interpretation. Besides, we also introduce the clinical applications of MRD detection in lymphoma.Keywords
This publication has 114 references indexed in Scilit:
- Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshopVirchows Archiv, 2023
- Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencingMolecular Carcinogenesis, 2022
- Circulating tumor DNA in Hodgkin lymphomaAnnals of Hematology, 2022
- Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphomaVirchows Archiv, 2022
- Computer‐aided diagnostic models to classify lymph node metastasis and lymphoma involvement in enlarged cervical lymph nodes using PET/CTMedical Physics, 2022
- Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 studyCancer, 2022
- Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease?Pediatric Blood & Cancer, 2021
- Progress and applications of mass cytometry in sketching immune landscapesClinical and Translational Medicine, 2020
- Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral HeterogeneityCytometry Part A, 2019
- MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR2019